Last $4.78 USD
Change Today -0.04 / -0.83%
Volume 43.7K
TLOG On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

tetralogic pharmaceuticals c (TLOG) Snapshot

Open
$4.85
Previous Close
$4.82
Day High
$5.10
Day Low
$4.73
52 Week High
03/11/14 - $9.28
52 Week Low
10/13/14 - $3.51
Market Cap
108.9M
Average Volume 10 Days
33.3K
EPS TTM
$-1.59
Shares Outstanding
22.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TETRALOGIC PHARMACEUTICALS C (TLOG)

Related News

No related news articles were found.

tetralogic pharmaceuticals c (TLOG) Related Businessweek News

No Related Businessweek News Found

tetralogic pharmaceuticals c (TLOG) Details

TetraLogic Pharmaceuticals Corporation operates as a clinical-stage biopharmaceutical company in the United States. The company focuses on discovering and developing novel small molecule therapeutics that mimic novel second mitochondrial activator of caspases to cause or enable abnormal cells, which are resistant to the body’s immune system to self-destruct. Its clinical-stage product candidate, Birinapant, is in Phase I and Phase II oncology clinical trials for multiple solid tumors and hematological malignancies. The company’s clinical and pre-clinical programs comprise an ongoing Phase I/II clinical trial of birinapant as a single agent in various blood cancers; a Phase I/II completed clinical trial of birinapant administered with irinotecan in colorectal cancer; and a Phase I/II clinical trial of birinapant administered with conatumumab in ovarian cancer, as well as an intention to start Phase I clinical trial in hepatitis B virus. It has collaboration with Amgen, Inc. for exploring the combination of birinapant administered with Amgen’s TRAIL receptor agonist antibody, conatumumab. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

28 Employees
Last Reported Date: 08/5/14
Founded in 2001

tetralogic pharmaceuticals c (TLOG) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $175.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $141.2K
Chief Operating Officer and Chief Medical Off...
Total Annual Compensation: $137.2K
Compensation as of Fiscal Year 2013.

tetralogic pharmaceuticals c (TLOG) Key Developments

Tetralogic Pharmaceuticals Corporation Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Clinical Update

TetraLogic Pharmaceuticals Corporation reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported loss from operations of $9,791,749 compared to $7,404,661 for the same period last year. Net loss attributable to common stockholders of $11,940,356 or $0.53 per diluted share compared to $9,330,118 or $0.42 per diluted share, adjusted net loss of $4,243,062 or $2.69 per diluted share compared to $7,338,263 or $1.38 per diluted share for the same period last year. Adjusted net loss was $8,463,182 or $0.38 per diluted share compared to $5,634,820 or $1.06 per diluted share for the same period last year. For the nine months, the company reported loss from operations of $33,785,603 compared to $17,990,894 for the same period last year. Net loss attributable to common stockholders of $35,958,979 or $1.63 per diluted share compared to $23,200,344 or $10.11 per diluted share, adjusted net loss of $11,414,475 or $8.93 per diluted share compared to $20,556,362 or $0.94 per diluted share for the last year. Adjusted net loss was $29,679,544 or $1.35 per diluted share compared to $17,049,295 or $7.43 per diluted share for the same period last year. The company is continuing enrollment in a Phase 1/2 study of birinapant in combination with conatumumab, Amgen's TRAIL agonist antibody, in 3rd line ovarian cancer. In December 2014 this clinical trial proceeded into a Phase 2a expansion based upon data in the Phase 1 portion of the trial.

TetraLogic Files Shelf Registration; Mulls Acquisitions

TetraLogic Pharmaceuticals Corporation (NasdaqGM:TLOG) has filed a Shelf Registration in the amount of $150 million. The net proceeds will be used for general corporate purposes, including working capital, continued development of product candidate pipeline, acquisitions, retirement of debt and other business opportunities.

TetraLogic Pharmaceuticals Corporation Announces Initiation of Randomized Phase 2 Clinical Trial of Shape in Subjects with Cutaneous T-Cell Lymphoma

TetraLogic Pharmaceuticals Corporation announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with early stage cutaneous Tcell lymphoma. SHAPE has been evaluated in a randomized, dose escalation, placebo-controlled Phase 1 clinical trial in early-stage CTCL subjects that met safety endpoints and demonstrated clinical activity. Four of fifteen patients receiving SHAPE attained an objective response as measured by a greater than 50% improvement in their Composite Assessment of Index Lesion Severity, or CAILS, score during and after 28 days of dosing. No placebo patients responded. The randomized Phase 2 trial will be conducted in approximately sixty subjects with Stage IA-IIA CTCL. The objectives of the Phase 2 clinical trial are to evaluate the dose, clinical effect at 6 months (based on CAILS score), time to response, and tolerability of treatment of >2% body surface area.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TLOG:US $4.78 USD -0.04

TLOG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TLOG.
View Industry Companies
 

Industry Analysis

TLOG

Industry Average

Valuation TLOG Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TETRALOGIC PHARMACEUTICALS C, please visit www.tetralogicpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.